The primary objective of the proposed pilot study is to determine the efficacy of oxymorphone
hydrochloride and propoxyphene/acetaminophen combination in prolonging the time to onset of
pain and reducing the severity of pain associated with walking in patients lumbar spinal
stenosis that have clinical symptoms of neurogenic claudication. Neurogenic claudication is
defined as movement induced leg pain, numbness, heaviness, or vague discomfort in part or all
of one or both legs provoked with walking and standing and relieved by sitting, squatting, or
forward flexion posturing. The secondary objective is to examine the functional benefit of
oxymorphone hydrochloride and propoxyphene/acetaminophen combination with respect to
improvement in duration and distance of walking.
Phase:
Phase 4
Details
Lead Sponsor:
University of Rochester
Collaborator:
Endo Pharmaceuticals
Treatments:
Acetaminophen Acetaminophen, dextropropoxyphene, drug combination Dextropropoxyphene Levopropoxyphene Oxymorphone